EMA Authorised: Zimbus Breezhaler (glycopyrronium bromide;Indacaterol (acetate);mometasone furoate) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Zimbus Breezhaler, a fixed-dose inhaler containing glycopyrronium bromide, indacaterol (acetate), and mometasone furoate for asthma, develope…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Glycopyrronium bromide (glycopyrronium bromide)
• Mometasone furoate (Mometasone furoate)
• Zimbus Breezhaler
• indacaterol (acetate) (indacaterol)

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: Novartis Europharm Limited. Decision date: 28/10/2025